Destiny Pharma PLC (DEST)

London
113.50
0.00(0.00%)
  • Volume:
    1,070
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    113.50 - 113.50

DEST Overview

Prev. Close
113.5
Day's Range
113.5-113.5
Revenue
-
Open
113.5
52 wk Range
60-250
EPS
-0.11
Volume
1,070
Market Cap
67.94M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
29,910
P/E Ratio
-
Beta
0.43
1-Year Change
71.97%
Shares Outstanding
59,861,921
Next Earnings Date
11 Apr 2022
What is your sentiment on Destiny Pharma PLC?
or
Market is currently closed. Voting is open during market hours.

Destiny Pharma PLC Company Profile

Employees
14

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing NTCD-M3 that is in phase III clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal that is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal, which is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Biofilm for the treatment of of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF Drugs for the treatment of respiratory, oral mucosa, and ocular infection diseases. Destiny Pharma plc has collaboration agreement with China Medical System Holdings Limited; research collaboration with the University of Southampton for targeting infections in diabetic foot ulcers and cystic fibrosis; research collaboration with the University of Sheffield; research collaboration with Aston University to investigate novel compounds from its XF-drug platform; collaboration with Cardiff University and Tianjin Medical University; and Collaboration with SporeGen Limited to co-develop treatment for COVID-19. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralSellSellStrong SellBuy
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellBuy
SummarySellStrong SellStrong SellStrong SellBuy
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.